Nanoparticle Albumin Bound Technology for Superior NAB-Paclitaxel Production with Biotest HSA

In this webinar Biotest, RCPE and Microfluidics will present a study and introduce the complete concept (high quality material, suitable method and the equipment which is scalable from lab-, pilot- and production volumes) for making a nab-paclitaxel formulation.

The first FDA approved formulation of nanoparticle albumin bound – paclitaxel is manufactured under the pharmaceutical name of Abraxane® and is an effective chemotherapeutic used in the treatment of advanced and spreading pancreatic cancers, metastatic breast cancers and non-small lung cancers.

Biotest recently conducted a study, evaluating the processability and properties of nanoparticle albumin bound - paclitaxel using the Biotest human serum albumin (HSA) and comparing it to the commercially available recombinant HSA. For producing the nab-paclitaxel, Microfluidizer® LM20 processor was used to achieve a mean particle size of 130 nanometers (as it is in Abraxane®) with a narrow size distribution, high reproducibility and scalability.

This study conducted in cooperation with RCPE (a research company with high expertise in nanoencapsulation technology) found the Biotest HSA to achieve similar results in producing nab-paclitaxel as the recombinant HSA while being more economical and therefore to be an excellent material for nab-paclitaxel production.

This overall concept should facilitate new projects for interested companies.

Best-in-class* Human Serum Albumin:
​​​​​​​the perfect solution for your formulation and
​​​​​​​cell culture applications

 

​​​​​​